Mologic Ltd – big in tiny science
Mologic is an independent healthcare diagnostics R&D company, located in Bedford, UK, employing 35 scientists and technicians.
Mologic’s research interests include inflammatory diseases, such as COPD and sepsis, infectious diseases, metabolic diseases and clinical immunology. We are skilled in the development and application of antibodies and assay test platforms, for the measurement of biomarkers of disease status. Our aim is to develop novel, disruptive technologies to improve and extend the application of in vitro diagnostic devices, particularly for point of care use, and have many patents in this area.
Mologic’s R&D team includes:
- experienced organic chemists (skilled in peptide and carbohydrate synthesis and protein modification),
- immunoassay scientists and technicians, experienced in development of classical (e.g. lateral flow and ELISA) and novel platforms (e.g. “ELTABA” enzyme activity assays),
- biochemists (molecular biologists, fermentation experts, microbiologists and immunologists),
- and experts in flow cytometry, electrochemistry, formulation chemistry, stability studies, regulatory affairs and CE Marking, clinical trial management, bioinformatics and data management.
Mologic has an extensive academic and business contacts network, including key opinion leaders and clinicians across a number of science and medical disciplines.
One of the main scientific themes of the Mologic programme is that of chronic inflammation, especially in relation to respiratory disease, metabolic syndrome and diabetes. Our objective is to discover novel combinations of biomarkers that can be integrated by simple algorithms in such a way as to predict and diagnose inflammatory disease, or progression of inflammatory disease. We also seek new biomarkers or new ways in which known biomarkers can be assayed, in order to improve their diagnostic utility (e.g. certain protease activities in urine).
Our research strategy usually starts with an antigen of interest. We design and synthesise an immunogen, raise antibodies, characterise and purify them, and integrate the antibodies (or related materials) into laboratory assays. Once the laboratory assays have been optimised and validated, we develop point-of-care or home-use versions. These may be integrated into multiplexed assays, in which combinations of biomarkers can be assayed simultaneously, in a convenient, user-friendly format.